---
schema_version: "secwatch.filing_event.v1"
accession: "0001818331-25-000128"
form_type: "8-K"
ticker: "WGS"
cik: "0001818331"
company_name: "GeneDx Holdings Corp."
filed_at: "2025-10-28T23:59:59+00:00"
generated_at: "2026-05-17T01:58:44.499304+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# GeneDx Q3 2025 revenue $116.7M (+52% YoY), adjusted net income $14.7M; raises full-year guidance

## Summary
- Q3 revenue $116.7M (+52% YoY); exome/genome revenue $98.9M (+65% YoY).
- Adjusted gross margin expanded to 74% from 64%; adjusted net income $14.7M vs $2.0M.
- Raised FY2025 revenue guidance to $425-428M; exome/genome growth 53-55% YoY.
- Granted FDA Breakthrough Device Designation for ExomeDx and GenomeDx tests.

## SEC filing metadata
- accession: 0001818331-25-000128
- form_type: 8-K
- ticker: WGS
- cik: 0001818331
- company_name: GeneDx Holdings Corp.
- filed_at: 2025-10-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/0001818331-25-000128-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1818331/000181833125000128/wgs-20251028.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001818331-25-000128
- JSON: https://secwatch.observer/filing/0001818331-25-000128.json
- Plain text: https://secwatch.observer/filing/0001818331-25-000128.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.